Rising Prevalence of Skin Cancer and Diabetes to Drive Growth of Skin Graft Market During 2021–2028
According to our new research study on “Skin Graft Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Graft Thickness, Applications, Equipment, and End Users,” the market is expected to reach US$ 1,673.5 million by 2028 from US$ 985.4 million in 2020. It is estimated to grow at a CAGR of 7.0% from 2021 to 2028. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
The key factors such as the increasing numbers of burn injuries and rising prevalence of skin cancer and diabetes drive the growth of the skin graft market. However, the high cost of skin grafting procedures and alternatives for skin grafts hinder the market growth.
Skin grafts are ideally preferred post-surgery for skin cancers. Skin grafts are generally referred for local postoperative radiotherapy (PORT) to ensure closure of surgical bed created during radiotherapy. According to Cancer Research UK, ~15,400 new melanoma skin cancer cases are registered in the UK every year, accounting for 42 new cases every day. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035. Likewise, according to the recent statistics published by the International Agency for Research on Cancer, in 2020, 19.3 million new cancer cases were registered, excluding 18.1 million for nonmelanoma skin cancer. Thus, an increase in the prevalence of skin cancer is likely to contribute to skin grafting in the coming future.
Diabetes is among the most common health conditions prevalent across the globe. According to the International Diabetes Federation’s (IDF) IDF Diabetes Atlas Ninth edition 2019, ~463 million adults were living with diabetes worldwide. The prevalence is estimated to be 700 million by 2045—nearly 79% of adults living with diabetes in low-and-middle incomes countries worldwide. Among the prevalence of diabetes, the proportion of type 2 diabetes is increasing at a much faster rate. According to the IDF, 374 million are at risk of developing type 2 diabetes in the coming future.
Among diabetic patients, wound healing is prolonged, which increases the risk of skin infections if it is not healed within a particular time. ~25% of diabetic patients are likely to develop foot ulcers once in their lifetime that often need advanced diabetic wound care. Therefore, there is an increase in demand for skin grafts to treat or cover diabetic foot ulcers by eliminating the chances of contracting skin infections. Thus, the high prevalence rate of skin cancer and diabetes is expected to drive skin graft market in the near future.
B. Braun Melsungen AG, Integra Life Sciences Corporation, Smith & Nephew, AVITA Medical, MiMedx, Organogenesis Inc, Tissue Regenix Group, Zimmer Biomet, De Soutter Medical, and Nouvag AG are among the leading companies operating in the skin graft market.
The report segments global Skin Graft market as follows:
By Product
- Autologous
- Allogeneic
- Xenogeneic
- Prosthetic
- Isogeneic
By Graft Thickness
- Split-Thickness
- Full-Thickness
- Composite Graft
By Equipment
- Dermatome
- General Surgical Instruments
- Consumables
- Others
By Application
- Burns
- Extensive Wound
- Skin Cancer
- Other Applications
By End Users
- Hospitals
- Ambulatory Surgical Centers
- Dermatology Clinics
By Geography
- North America
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of APAC
- Middle East & Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Contact UsContact Person: Sameer JoshiPhone: +1-646-491-9876Email Id: sales@reportsweb.com
